

meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri A. Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2018-17042 Filed 8-8-18; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Name of Committee: Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH).

Dates: October 16–October 18, 2018.

Time: 8:00 a.m.–5:00 p.m., EDT.

Place: Embassy Suites, 1900 Diagonal Road, Alexandria, VA 22314.

Agenda: The meeting will convene to address matters related to the conduct of Study Section business and for the study section to consider safety and occupational health-related grant applications.

For Further Information Contact: Nina Turner, Ph.D., Scientific Review Officer, NIOSH, 1095 Willowdale Road, Morgantown, WV 26506, (304) 285-5976; nturner@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2018-17043 Filed 8-8-18; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0558]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Disclosures in Professional and Consumer Prescription Drug Promotion

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).

DATES: Fax written comments on the collection of information by September 10, 2018.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to aira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-NEW and title “Disclosures in Professional and Consumer Prescription Drug Promotion.” Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrahi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Disclosures in Professional and Consumer Prescription Drug Promotion

OMB Control Number 0910-NEW

I. Background

Section 1701(a)(4) of the Public Health Service Act (42 U.S.C. 300u(a)(4)) authorizes FDA to conduct research relating to health information. Section 1003(d)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes

FDA to conduct research relating to drugs and other FDA regulated products in carrying out the provisions of the FD&C Act.

FDA regulates prescription drug advertising and promotional labeling directed to healthcare professionals (HCPs) and consumers (section 502(a) and (n), respectively, of the FD&C Act (21 U.S.C. 352(a) and (n))). In the course of promoting their products, pharmaceutical sponsors (sponsors) may present a variety of information including the indication, details about the administration of the product, efficacy information, and clinical trial data. To present often complicated information concisely, sponsors may not include relevant information in the body of the text or visual display of the claim. Additionally, sponsors may not always present limitations to the claim in the main body of the text or display. In these cases, sponsors typically include disclosures of information somewhere in the promotional piece.

There is limited published research on disclosures in prescription drug promotion, either directed to consumers or to HCPs. The use of disclosures is one method of communicating information to HCPs and consumers about scientific and clinical data, the limitations of that data, and practical utility of that information. These disclosures may influence HCP and consumer comprehension and decision making, and may affect how and what treatment HCPs prescribe for their patients. Previous research on the effectiveness of disclosures has been conducted primarily in the dietary supplement arena (Refs. 1-4). Thus, the proposed research will examine the effectiveness of clear and conspicuous disclosures in prescription drug promotion directed to both populations. The purpose of our study is to determine how useful disclosures regarding prescription drug information are when presented prominently and adjacent to claims.¹ Specifically, are HCPs and consumers able to use disclosures to effectively frame information in efficacy claims in prescription drug promotion?

To address this research question, we have designed a set of studies that cover both consumers and HCPs, as well as three presentations addressing different

¹ The Federal Trade Commission (FTC), which regulates the advertising of non-prescription drug products as well as other non-FDA regulated products (e.g., package goods, cars, etc.) issued a specific position on disclosures (Ref. 5) for the advertising it regulates. Specifically, FTC explains that disclosures must be “clear and conspicuous”; in other words, in understandable language, located near the claim to be further clarified, and not hidden or minimized by small font or other distractions.

types of information: Scope of treatment, ease of use, and statistical significance (see table 1). The scope of treatment information to be tested can be thought of as disease-awareness information; that is, a broader discussion of a medical condition that includes disease characteristics beyond what the promoted drug has been shown to treat. The disclosure for this condition will focus on the disease characteristics that the product has been shown to treat. The ease of use information to be tested is a simple claim of easy drug administration,

followed by a disclosure that includes material information about drug administration. Finally, the statistical significance information to be tested includes a presentation of efficacy analyses, followed by a disclosure revealing that the results of the presented analyses were not statistically significant, and thus must be viewed with considerable caution. We selected these types of information because they are commonly seen in promotional material.

Each participant will view three different professionally developed mock

promotional print pieces for different prescription drug products that mimic currently available promotion. For each of the three promotional pieces, they will be randomized to see an ad with a weak disclosure, a strong disclosure, or no disclosure. We will manipulate the strength of disclosure by including additional concluding information (strong) or not (weak) in the disclosure statement. In all cases, disclosures will be adjacent to claims and written in font clear enough to be detected.

TABLE 12—IDENTICAL STUDY DESIGNS FOR SAMPLES OF HCPs AND CONSUMERS

Type of claim	Level of disclosure		Control
	Weak	Strong	
Study A: HCPs			
Scope of Treatment	Evidence Only	Evidence + Conclusion	No Disclosure
Ease of Use	Evidence Only	Evidence + Conclusion	No Disclosure
Statistical Significance	Evidence Only	Evidence + Conclusion	No Disclosure
Study B: Consumers			
Scope of Treatment	Evidence Only	Evidence + Conclusion	No Disclosure
Ease of Use	Evidence Only	Evidence + Conclusion	No Disclosure
Statistical Significance	Evidence Only	Evidence + Conclusion	No Disclosure

We will analyze the results of the scope of treatment disclosures, the ease of use disclosures, and the statistical significance disclosures independently of each other, even though each participant will see one of each. The claims and disclosures are different enough that practice effects should be moderated, but we will counterbalance the order of ads shown to minimize potential bias.

Because promotional pieces intended for HCPs and consumers have different levels of complexity and medical depth, and because the amount of knowledge expected between the two groups differs, the studies will use separate mock promotional pieces and ask slightly different comprehension questions of each group. We will maintain as much similarity across groups as possible for descriptive comparisons.

Both consumers and HCPs will be recruited from internet panels. Because promotional pieces will represent three different medical conditions, we will obtain a general population sample of consumers and a HCP sample of primary care physicians. We will exclude individuals who are employees of the U.S. Department of Health and Human Services or who work in pharmaceutical, advertising, or marketing settings because their

knowledge and experiences may not reflect those of the typical healthcare provider or consumer. Eligible participants who agree to participate voluntarily in this survey will view mock promotional pieces and answer questions about their comprehension of the main messages in the promotion, perceptions of the product, attention to disclosures and intention to ask a HCP about it (consumers) or to prescribe the product (HCPs). Questionnaires are available upon request.

Pretests will be conducted before conducting the main studies to ensure the mock promotional pieces are realistic and that the questionnaire flows well and questions are reasonable. We will supplement the findings of the pretests with two small eye-tracking studies. Researchers use eye-tracking technology to capture viewing behavior that is independent of self-report. The technology measures where and for how long participants glanced at or examined particular parts of a display. It has been used in studies of consumer print advertising (Refs. 6–8) and internet promotion (Refs. 9 and 10). To our knowledge, there is little or no published research using eye-tracking technology with HCPs.

We will use these small eye-tracking studies to determine what parts of each promotional piece consumers and HCPs

actually viewed. Specifically, we will be able to determine whether they looked at the disclosure statement at all, and we can obtain a rough idea of how long they looked at it. This data will complement the self-reported items on the questionnaire. Moreover, we will use this data, as well as the pretest data, to improve the main studies. For this part of the study, 20 consumers and 20 HCPs will view the promotional pieces.

In the **Federal Register** of June 14, 2017 (82 FR 27268), FDA published a 60-day notice requesting public comment on the proposed collection of information. Four comments were received. Responses to those comments follow. For brevity, some public comments are paraphrased and therefore may not reflect the exact language used by the commenter. We assure commenters that the entirety of their comments was considered even if not fully captured by our paraphrasing in this document. The following acronyms are used here: DTC = direct-to-consumer; HCP = healthcare professional; FDA and “The Agency” = Food and Drug Administration; OPDP = FDA’s Office of Prescription Drug Promotion.

The first public comment responder (*regulations.gov tracking number 1kl-8y39-rtvb*) included 25 individual

comments, to which we have responded.

Comment 1a (summarized): FDA is conducting too much research without articulating a clear, overarching research agenda or adequate rationales on how the proposed research related to the goal of further protecting public health. The Agency should publish a comprehensive list of its prescription drug advertising and promotion studies from the past 5 years and articulate a clear vision for its research priorities for the near future.

Response 1a: OPDP's mission is to protect the public health by helping to ensure that prescription drug information is truthful, balanced, and accurately communicated, so that patients and healthcare providers can make informed decisions about treatment options. OPDP's research program supports this mission by generating scientific evidence to help ensure that our policies related to prescription drug promotion will have the greatest benefit to public health. Toward that end, we have consistently conducted research to evaluate the aspects of prescription drug promotion that we believe are most central to our mission, focusing in particular on three main topic areas: Advertising features, including content and format; target populations; and research quality. Through the evaluation of advertising features we assess how elements such as graphics, format, and disease and product characteristics impact the communication and understanding of prescription drug risks and benefits; focusing on target populations allows us to evaluate how understanding of prescription drug risks and benefits may vary as a function of audience; and our focus on research quality aims at maximizing the quality of research data through analytical methodology development and investigation of sampling and response issues.

Because we recognize the strength of data and the confidence in the robust nature of the findings is improved through the results of multiple converging studies, we continue to develop evidence to inform our thinking. We evaluate the results from our studies within the broader context of research and findings from other sources, and this larger body of knowledge collectively informs our policies as well as our research program. Our research is documented on our homepage, which can be found at: <https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsand tobacco/cder/ucm090276.htm>. The website includes links to the latest **Federal Register** notices and peer-

reviewed publications produced by our office. The website maintains information on studies we have conducted, dating back to a survey of DTC attitudes and behaviors conducted in 1999.

Comment 1b (The commenter provided a summary of the comments followed by a more detailed description of the same comments. For brevity, the summary of comments has been omitted and only the specific comments [1b through 1y] are provided below. The commenter's full comments may be accessed at regulations.gov via tracking number 1kl-8y39-rtb) (verbatim): It is not clear from this description whether the study will yield useful information to evaluate whether disclosures provide appropriate contextual information in certain communications, whether such disclosures can be made more effective, and where the disclosures are necessary to ensure communications are truthful and non-misleading. The Agency should provide significantly more detail regarding the design of the study, the proposed disclosures, the mock promotional pieces, and the information it seeks to collect.

Response 1b: We have provided the purpose of the study, the design, the population of interest, and have provided the questionnaire to numerous individuals upon request. These materials have proven sufficient for others to comment publicly, and for academic experts to peer-review the study successfully. We do not make draft stimuli public during this time because of concerns that this may contaminate our participant pool and compromise the research.

Comment 1c (summarized): After pretesting, the Agency should make available revised questionnaires, data collection methodologies, and stimuli.

Response 1c: In this current notice, we provide the revised design as based on academic peer reviewers, cognitive interviewing, and public comments. The revised questionnaire is also available upon request. Our full stimuli are under development during the PRA process. We do not make draft stimuli public during this time because of concerns that this may contaminate our participant pool and compromise the research. Individuals are welcome to inquire about the progress of the study and any changes from the pretests will be communicated at that time.

Comment 1d (summarized): FDA should base mock promotional stimuli on realistic promotional pieces.

Response 1d: We have done this. Our stimuli are modified from actual promotional pieces in the marketplace to disguise the original product.

Comment 1e (summarized): It is unclear whether such disclosures will contain relevant information ordinarily provided in promotional materials.

Response 1e: The goal of our research is to obtain answers to questions about prescription drug promotion that will inform the Agency and stakeholders. Thus, we strive in all of our studies to make our mock promotional pieces as realistic as possible. That includes any disclosures that we may include in testing. Also, please see response to comment 1d.

Comment 1f (verbatim): FDA seems to have an overly broad conception of the need for disclosures for "scope of treatment" communications. In the Notice, FDA describes this type of communication as "a disease-awareness claim; that is, a broader discussion of a medical condition that may include disease characteristics beyond what the promoted drug has been shown to treat." Where a disease awareness communication discusses a disease in a manner beyond what the promoted drug has been shown to treat, but does so in a balanced manner without implying any particular treatment benefits from the associated drug, it should be viewed as providing helpful general background information on the disease, and not as making an off-label claim for the drug. In those circumstances, there should be no need for any disclosure about the limits of use of the drug. FDA should clarify its understanding of "scope of treatment" claims and make its proposed claims and disclosures available for public comment.

Response 1f: Previous research has demonstrated that presenting study participants with information about the consequences of a disease, particularly when the information was integrated into one print ad with information about a particular drug, resulted in false beliefs that the advertised drug prevented those consequences.² The "scope of treatment" claims that are included in this research are embedded in mock promotional materials, juxtaposed with specific efficacy information about the mock drug products. As such, they will likely imply "particular treatment benefits from the associated drug." This research will help us to evaluate the usefulness of a disclosure in relation to this type of information when it is found in promotional pieces. Also, please see response to comment 1c.

² Aikin, K.J., H.W. Sullivan, and K.R. Betts, (2016). "Disease information in direct-to-consumer prescription drug print ads." *Journal of Health Communication*, 21(2), pp. 228-239.

Comment 1g (verbatim): FDA states that the “ease of use” claim “is a simple claim of easy drug administration that omits specific important details that contribute to a more difficult drug administration than suggested.” This statement appears to imply that all ease of use claims are misleading, where the Agency perhaps intends to clarify that validated and non-misleading “ease of use” claims may require a disclosure or more context. FDA should clarify its understanding of “ease of use” claims, and, in testing, ensure it does not test overly misleading base claims for “ease of use” that would be difficult to contextualize with a disclosure statement and hence would bias the results of its study. Such claims should be made available for public comment.

Response 1g: FDA did not intend to imply that all ease of use claims are misleading or that all ease of use claims would necessarily require a disclosure. FDA agrees that some ease of use statements require a disclosure or more context and intends to evaluate one such example with this research. We have revised the description of the study in this notice to clarify. Also, please see response to comment 1c.

Comment 1h (verbatim): FDA states that the “statistical significance” claim “will be one in which the disclosure reveals that the presented analyses were not statistically significant, and thus must be viewed with considerable caution.” It is not clear what content FDA intends to test for this type of claim. We encourage FDA to clarify how it intends to present “not statistically significant” analyses for testing in order to ensure such claims are presented with appropriate contextual information. Such claims should be made available for public comment.

Response 1h: Please see responses to comment 1c, 1d, and 1e.

Comment 1i (summarized): The Agency should clarify what distinctions will be made between HCP and consumer pieces.

Response 1i: As our mock promotional pieces have been adapted from existing materials in the public domain, the materials directed to HCPs and to consumers vary in similar ways to what can currently be seen in the public domain. For example, materials directed to HCPs tend to have more data, more technical medical language, and more text in general. Consumer pieces are generally written in plainer language and generally do not include as much data and statistical information. Our pieces are highly realistic as they were developed from actual promotional pieces.

Comment 1j (verbatim): The Agency proposes that consumer and HCP subjects will be recruited from internet panels, indicating that the study will be conducted using an electronic format. Because the proposed research topic is not dependent on an electronic medium, FDA should consider testing non-electronic media as well, including printed promotional pieces.

Response 1j: Although our study will be conducted via the internet, we will show participants mock print materials in .pdf format.

Comment 1k (verbatim): The Agency proposes to use eye-tracking studies to complement the self-reported items on the questionnaire and to improve the main studies. [The commenter] encourages the Agency to use this technology in conjunction with other inputs (for example, qualitative research) to understand why subjects are looking at a portion of the proposed materials, rather than to draw conclusions that such portions were viewed. Additionally, an explanation of the use of eye-tracking technology should also be included during the subject enrollment process.

Response 1k: FDA plans to collect and analyze eye-tracking (physical measures of attention) data in conjunction with other measures, including cognitive interviews. To avoid the potential for priming effects, the eye-tracking component of the study will not be explained to recruited individuals before they report for their in-person sessions. However, participants will be made aware of the eye-tracking component during the informed consent process.

Comment 1l (summarized): The commenter recommends increasing the sample size of the eye-tracking components to ensure more robust data.

Response 1l: Our primary method of analysis of the eye-tracking data will be examination of gaze plots coupled with self-report data provided by participants. Thus, eye-tracking results will be examined on an individual, rather than aggregate, level. Furthermore, the eye-tracking studies included in this research are intended as qualitative, formative studies; they will be used to inform any necessary changes to the stimuli before the main studies. Formative eye-tracking studies such as these are often executed with sample sizes as small as five participants.³ In our experience, a sample of 20 participants in each

population ensures that we will collect fully useable data from a minimum of 15 participants in each population. Used as an observation tool, eye-tracking complements the other data collected to increase discoverability of specific events and confidence in our qualitative findings.

Comment 1m (summarized): The commenter recommends limiting the participant sample to disease sufferers rather than a general population sample.

Response 1m: We carefully consider the type of sample to use in each of our studies. In the current study, the population of sufferers for the conditions addressed by our stimuli (*i.e.*, chronic obstructive pulmonary disease (COPD), chronic iron overload, and high blood pressure) are varied. Because we are showing participants more than one ad, we chose not to select diagnosed populations or specialists.

Comment 1n (summarized): FDA should recruit a demographically and geographically diverse sample.

Response 1n: We agree and we plan to recruit individuals with a range of gender, race, ethnicity, and, as much as possible within an internet sample, socioeconomic status. For the consumer sample, we aim for a sample with 60 percent of people who have some college or less. An advantage of sampling via internet panel is that we have access to individuals in all parts of the United States.

Comment 1o (verbatim): FDA should capture whether subjects comprehend certain information disclosed in the mock promotional pieces, even if the subject does not recall information on the specifics. Currently, open-ended and recall questions (*e.g.*, Consumer Questionnaire Q2–Q3; HCP Questionnaire Q2–Q3) ask test subjects to identify certain information regarding the featured drug products (what a mock drug product is specifically “used for” or “not approved for”). It is not clear why such an open-ended format or questions are necessary for the research purpose of the study, as subjects could recognize a limit to the efficacy being presented even if they do not follow or recall all of the details of a disclosure.

Response 1o: We do intend to capture what information has been observed in the mock promotional pieces, and we do this through the open-ended and recall questions. It is common practice to include open-ended and closed-ended questions in one research study, as they tend to complement each other. Open-ended questions allow responses that have not been prompted by particulars, which is not the case with closed-ended questions. Closed-ended questions

³ Pernice, K. and J. Nielsen, (2009). “How to Conduct Eyetracking Studies.” https://media.nngroup.com/media/reports/free/How_to_Conduct_Eyetracking_Studies.pdf.

provide a more efficient way of obtaining information.

Comment 1p (summarized): FDA should ensure that terms used in the consumer pieces are consumer-friendly.

Response 1p: We agree and always review our mock consumer pieces for lay language. The terms mentioned by the commenter (e.g., chronic iron overload, COPD, lung function, scientific evidence, effectiveness, statistically significant) will be used in the HCP materials. However, we also strive to make our materials as realistic as possible, and in this case, we have modified existing DTC pieces for consumers. If they used a term (e.g., COPD), and OPDP reviewers agreed that this is common and acceptable, we maintained it in our mock pieces.

Comment 1q (summarized): FDA should consider changing the sliding scale format of Q4.

Response 1q: We carefully develop each question of our questionnaires, taking into account language and response options. No cognitive interview participant reported confusion with this sliding scale question. Without scientific justification for changing the response format of this question, we will maintain the current format.

Comment 1r (verbatim): In a study setting, subjects may be prone to pay attention to more or all of the information presented throughout the study, including claims designed to be intentionally misleading. As a result, subjects are more likely to be biased based on the strength or weakness of the claims and disclosures presented. The Agency should address what efforts it will take to avoid response bias by presenting these varying degrees of disclosures.

Response 1r: The study is designed so that participant will be randomly assigned to condition. Moreover, the only aspect of the participants' experiences that will be varied in the study will be the manipulations that we have described. Any individual differences in attention or ability or potential biases should be spread across experimental conditions. Thus, if we find differences between and among conditions, we can be reasonably sure that the manipulations caused the differences. We have not found in the past that our participants spend an inordinate amount of time viewing stimuli, but we will be careful to place the research in context when we interpret the data.

Comment 1s (verbatim): The Consent Text introduction should not state that the survey is being conducted "on behalf of the U.S. Food and Drug

Administration." This statement could potentially influence subjects' responses to study questions. Instead, this information might be provided at the conclusion of the study.

Response 1s: In previous studies, we took this same view and typically used "Department of Health and Human Services." We will incorporate this change.

Comment 1t (verbatim): Questions regarding statements in ads (Consumer Questionnaire Q10, Q20, Q30; HCP Questionnaire Q12, Q22, Q33) should be the first questions presented following the subjects' viewing of a promotional piece. A subject will likely recall the statements that appeared in the promotional piece most accurately immediately after reviewing the piece and before answering other questions that could influence their selection of answers.

Response 1t: As with all other aspects of study design, we carefully develop questionnaires with order effects in mind. Therefore, we chose to include questions regarding perception of efficacy or ease of use, information seeking, and behavioral intention first because it is important that participant responses to these items be based solely on the information presented in the ads. The questions referenced by the commenter also include incorrect recall items, which could potentially bias responses to later questions if the order was changed. Additionally, repeated exposures to the correct recall items in the above-referenced questions could have a reinforcing effect that could confound results.

Comment 1u (verbatim): In the Consumer Questionnaire, an "FDA employee" category, similar to S7 and S8, should be added to the Screener Survey. These individuals should also be terminated from the study.

Response 1u: We will revise question S8 to read, "Do you work for a pharmaceutical company, an advertising agency, a market research company, or the U.S. Department of Health and Human Services?" to capture these individuals, as suggested.

Comment 1v (verbatim): In the Consumer Questionnaire, Q8–Q9 should be presented prior to Q6–Q7 in order to prevent bias in favor of non-HCP sources. Similarly, Q19 should appear before Q18, and Q28 should appear before Q27.

Response 1v: We will reorder the questionnaire as the commenter suggested.

Comment 1w (summarized): We recommend that Q8–Q9, Q19, and Q28 be expanded to more fully evaluate the role of the prescriber in aiding

consumers' understanding of disclaimers in promotional materials.

Response 1w: HCPs are often a very important source of information about prescription drugs. However, when prescription drugs are promoted directly to consumers, they may be more likely to look for information on their own before taking steps to consult their HCPs. We have taken this into account in this study by examining the responses of both consumers and HCPs.

Comment 1x (verbatim): In the HCP Questionnaire, Q5, Q7, and Q29 should be omitted. Comparative efficacy is highly dependent on the particular HCP subject's experience outside the experiment setting; this question thus may lead to highly variable results. Further, how the drug featured in the mock promotional communication compares to other prescription medications has no relevance to FDA's stated study goals. Questions regarding comparative efficacy should thus be omitted from the proposed HCP Questionnaire.

Response 1x: Comparative efficacy questions are another way to assess how HCPs respond to prescription drug promotion. Any subjective experiences outside the experiment setting should fall out because HCPs will be randomly assigned to conditions. The questions are relevant to our study because HCPs make comparative decisions each time they make a prescribing decision.

Comment 1y (verbatim): In the HCP Questionnaire, Q34 does not appear to provide appropriate programming instructions for the scenario in which Q33_A=01 and Q33_D=01. FDA should confirm that Q33 may be asked if subjects select both Q33_A and Q33_D, and provide that this question may be repeated for both responses. The variable label text for Q34 should also be rewritten as follows: "How much did the statement [disclosure] influence your assessment of the scientific evidence for [D]esyflux?"

Response 1y: Q33 asks whether participants have seen any of the listed statements. Q34 is asked for each of Q33_A and Q33_D when they respond affirmatively to that statement in Q33. Thus, participants who chose option 01 for both items will see two separate questions. We will make the suggested changes to Q34.

The second public comment responder (*regulations.gov tracking number 1kl-8y11-169c*) included four individual comments, to which we have responded.

Comment 2a (summarized): FDA should give consideration to the representativeness of online study

volunteers to the general public who will view print ads.

Response 2a: This is an excellent point and one to which we have given much thought. As with all research, there is a tradeoff of efficiencies when it comes to collecting information from volunteers. Recruiting from internet panels is a relatively economical way to achieve large sample sizes from all across the United States, making it possible to achieve geographic and urban/rural diversity in a way that was not previously possible. However, it is true that members of lower socioeconomic classes do not have the same access to computers and the internet, and therefore our sample may be skewed toward individuals who have higher education and/or income. We have attempted to mitigate this issue by aiming for recruitment of 60 percent of individuals with some or no college and 40 percent of individuals with a college degree or more.

While it is important to note that random assignment of respondents to experimental conditions provides us the ability to make causal claims about our findings, we do note that truncating the population from which we sample is a limitation of the study and will describe this in any publication or presentation that results from the data.

Comment 2b (verbatim): We suggest that the study include electronic advertisements in addition to print advertisements to account for and reflect changes in consumer consumption of media, including the increase of electronic promotion and advertising of products by sponsors.

Response 2b: We agree that more information and promotion is moving to electronic presentations, including the internet, mobile applications, and other communication formats. However, the questions we ask in this current study are fundamental questions that should not differ based on presentation format. Moreover, our print ads are similar to what might be shown on a website, which is a prominent electronic format. We have other studies ongoing that are examining other electronic presentation modes (e.g., 82 FR 32842, July 18, 2017).

Comment 2c (summarized): If the three levels of disclosure are to be strong, weak, and none, we recommend considering the following levels of disclosure:

- Additional concluding information makes it strong
- Less additional information makes it weak
- No additional information makes it none

Response 2c: Thank you for clearly investing time and energy in responding to this study design. The suggested levels of disclosure are effectively the same as what we have included in our study design. The weak disclosure provides some additional information, while the strong disclosure provides both the additional information and an explicit conclusion based on the information.

Comment 2d (summarized): FDA should keep in mind that stronger disclosures may be longer, therefore eye-tracking time may reflect length, not necessarily effectiveness.

Response 2d: The commenter is correct in that a longer block of text will generally result in a longer gaze fixation. We have taken steps to keep the stronger disclosures as close as possible in length to the weaker disclosures. However, as noted previously, eye-tracking outcomes will be analyzed qualitatively. Our primary interest is whether the disclosure was attended to—the length of attention is of less interest in this case.

The third public comment responder (*regulations.gov tracking number 1kl-8y16-bf58*) included five individual comments, to which we have responded.

Comment 3a (summarized): The commenter assumes that stimuli will conform to FDA regulations and requirements in non-study aspects and will not overdramatize claims versus disclosures.

Response 3a: All stimuli will conform to FDA regulations, as reviewed by OPDP reviewers. Additionally, we have designed the materials to fall within realistic parameters, thus the claims and disclosures are representative of what we may see in the marketplace.

Comment 3b (summarized): The commenter includes a section titled “Comments on the Brief Summary and Provision of Risk Information in Advertising” wherein FDA is encouraged to continue to consider the purpose and practical limits of advertising.

Response 3b: FDA agrees that a consideration of the purpose and practical limits of prescription drug promotion will guide the development of research projects. Otherwise, the comment appears to fall outside the scope of this particular proposed research.

Comment 3c (summarized): Add “Don’t Know” options for questions about perceived effectiveness in the consumer questionnaire.

Response 3c: Questions about perceived effectiveness by definition involve subjective rather than objective

assessments of effectiveness. Participants have the option to skip these questions if they wish.

Comment 3d (verbatim): We suggest also including questions to capture whether respondents have a general understanding that there are limitations to the data and information being presented, even if they do not recall specific information and disclosure statements.

Response 3d: This is a good suggestion, but it is important to phrase such questions appropriately. For example, simply asking participants if they believe the data is thorough and complete or that the data has limitations is not likely to yield useful information. However, there are several validated skepticism scales that approach this idea of trusting the validity of presented information. Although these items are not tied to data specifically, they will provide some information for us about how much individuals rely on the data. We have added two questions near the end of the survey to address this issue.

Comment 3e (summarized): The commenter recommends deleting “. . . from a source other than your healthcare provider” from questions 6 and 7.

Response 3e: Because we ask about seeking information from a HCP in other questions, we will retain this distinction in Q6 and Q7 for clarity.

The fourth public comment responder (*regulations.gov tracking number 1kl-8y38-nOp8*) included eight individual comments, to which we have responded.

Comment 4a (summarized): The commenter is supportive of the research.

Response 4a: Thank you for your support.

Comment 4b (summarized): The commenter suggests carefully selecting medical conditions to ensure a range of therapeutic areas. Specifically, they suggest one life-threatening condition (e.g., cardiovascular conditions leading to stroke), one chronic condition (e.g., atopic dermatitis), and one non-life-threatening and non-chronic condition (e.g., urinary tract infection).

Response 4b: FDA believes this proposed range of medical conditions is a great way to choose therapeutic categories. For the current study, however, we limited ourselves to medical conditions that have existing promotional pieces that include a variety of limitations that can be feasibly explained in a disclosure. We will keep the commenter’s approach in mind and apply it in future research when possible.

Comment 4c (summarized): The commenter suggests selecting a diversity

of participants, including gender, race, ethnicity, socioeconomic status, etc., to better represent the population at large. Also, FDA should consider inclusion and exclusion criteria for HCPs and consumers carefully.

Response 4c: We agree that these characteristics are important and strive to obtain representativeness across a variety of personal demographics. Although we will aim to recruit a diverse group of participants with sufficient variation on demographic characteristics such as gender, race, age, and education, we note that this study features random assignment to condition, whereby these demographic characteristics should have an equal chance of occurring. In terms of HCPs, we will include them if they are primary care physicians, and will work to recruit a sample with sufficient diversity on demographic characteristics as noted above.

Comment 4d (verbatim): It is critical that FDA evaluate the merits of unbiased introduction by not presenting a promotional piece to HCPs with specialty in the same therapeutic category.

Response 4d: For this study, we will be recruiting only primary care

physicians and not specialists. Thus, while any given participant may have experience treating one or more of the conditions represented by our stimuli, none should have specialties in the respective therapeutic categories.

Comment 4e (summarized): The commenter encourages the use of a health literacy competency tool such as a readability calculator to ensure consumers can understand the language.

Response 4e: We agree that the plain language communication of information is critical for the best public health outcomes. Nevertheless, our aim in this study is to test promotional materials that are available in the public domain. Although we have disguised the products and campaigns in our mock stimuli, all pieces are derived directly from promotion in the marketplace. We feel this is important to ensure that our study is relevant.

Comment 4f (summarized): The commenter recommends recruiting through hospitals, doctor offices, and clinics rather than via the internet. The commenter suggests that this will expand on the pool of participants, help minimize potential bias, and ensure the entire population of the United States is

represented as not everyone has access to or uses the internet.

Response 4f: Please see our response to comment 2a.

Comment 4g (summarized): The commenter recommends conducting subgroup analyses, such as with older adults.

Response 4g: We will examine covariates including age, race, and education level to determine whether these variables have any effect on our findings. This study is not designed to conduct between-subgroup analyses. If we detect relevant trends, such subgroup analyses may become good candidates for future studies.

Comment 4h (verbatim): [The commenter] recommends that the FDA communicate the actions they will take based on the study results and analysis. We also encourage FDA to provide further communication about when FDA will publish the study results, how the study results will be applied, and how this will impact the work of FDA.

Response 4h: Please see our response to comment 1a.

FDA estimates the burden of this collection of information as follows:

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN ¹

Activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours ²
Consumers					
Pretest Screener	833	1	833	0.03 (2 minutes)	25
Pretest	500	1	500	0.33 (20 minutes)	165
Eye-Tracking Screener	80	1	80	0.08 (5 minutes)	7
Eye-Tracking Study	20	1	20	1	20
Main Study Screener	2,500	1	2,500	0.03 (2 minutes)	75
Main Study	1,500	1	1,500	0.33 (20 minutes)	495
HCPs					
Pretest Screener	735	1	735	0.03 (2 minutes)	22
Pretest	500	1	500	0.33 (20 minutes)	165
Eye-Tracking Screener	80	1	80	0.08 (5 minutes)	7
Eye-Tracking Study	20	1	20	1	20
Main Study Screener	2,206	1	2,206	0.03 (2 minutes)	67
Main Study	1,500	1	1,500	0.33 (20 minutes)	495
Total					1,563

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

² Rounded to the next full hour.

II. References

The following references are on display in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852 and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also

available electronically at <https://www.regulations.gov>. FDA has verified the website addresses, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

1. Dodge, T. and A. Kaufman. "What Makes Consumers Think Dietary Supplements Are Safe and Effective? The Role of

Disclaimers and FDA Approval." *Health Psychology*, 26(4), 513–517. (2007).
 2. Dodge, T., D. Litt, and A. Kaufman. "Influence of the Dietary Supplement Health and Education Act on Consumer Beliefs About the Safety and Effectiveness of Dietary Supplements." *Journal of Health Communication: International Perspectives*. 16(3), 230–244. (2011).

3. Mason, M.J., D.L. Scammon, and X. Feng. "The Impact of Warnings, Disclaimers and Product Experience on Consumers' Perceptions of Dietary Supplements." *Journal of Consumer Affairs*, 41(1), 74–99. (2007).
4. France, K.R. and P.F. Bone. "Policy Makers' Paradigms and Evidence from Consumer Interpretations of Dietary Supplement Labels." *Journal of Consumer Affairs*, 39(1), 27–51. (2005).
5. FTC. "Full Disclosure." Accessed at: <https://www.ftc.gov/news-events/blogs/business-blog/2014/09/full-disclosure> (September 23, 2014) Last accessed on June 22, 2018.
6. Higgins, E., M. Leinenger, and K. Rayner. "Eye Movements When Viewing Advertisements." *Frontiers in Psychology*, 5, 210. (2014).
7. Pieters, R., M. Wedel, and R. Batra. "The Stopping Power of Advertising: Measures and Effects of Visual Complexity." *Journal of Marketing*, 74(5), 48–60. (2010).
8. Thomsen, S. and K. Fulton. "Adolescents' Attention to Responsibility Messages in Magazine Alcohol Advertisements: An Eye-Tracking Approach." *Journal of Adolescent Health*, 41, 27–34. (2007).
9. Simola, J., J. Kuisma, A. Öörni, L. Uusitalo, et al. "The Impact of Salient Advertisements on Reading and Attention on Web pages." *Journal of Experimental Psychology: Applied*, 17(2), 174–190. (2011).
10. Wedel, M. and R. Pieters. "A Review of Eye-Tracking Research in Marketing." In *Review of Marketing Research*, vol. 4 (pp. 123–147), N. K. Malhotra (Ed.). Armonk, New York: M. E. Sharpe. (2008).

Dated: August 3, 2018.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2018–17045 Filed 8–8–18; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2018–D–2614]

Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug

Substances." This guidance has been developed to provide manufacturers with recommendations for submission of new drug applications (NDAs), investigational new drug applications (INDs), or abbreviated new drug applications (ANDAs), as appropriate, for orally administered immediate-release (IR) drug products that contain highly soluble drug substances. The guidance is intended to describe when a standard release test and criteria may be used in lieu of extensive method development and acceptance criteria-setting exercises.

DATES: The announcement of the guidance is published in the **Federal Register** on August 9, 2018.

ADDRESSES: You may submit either electronic or written comments on Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and

identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA–2018–D–2614 for "Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- *Confidential Submissions—*To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug